CRDF
Cardiff Oncology, Inc.
$1.50
-3.23%
$106.0M
No data for this timeframe.
Vol
Market Cap$106.0M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (86%)
Inst. Holders7 funds
Inst. Value$14.1M
Inst. Activity2 buys / 1 sells
Reddit Sentiment64° Warm
SEC Reports6
Press Releases4
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001213037·Prev Close $1.55
Recent Activity
Jun 3, 2026
SEC
Cardiff Oncology released an investor presentation detailing interim Phase 2 CRDF-004 data for onvansertib in first-line
8-K — Impact 7/10
Jun 2, 2026
fda
Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting
<p align="center"><em>- The trial achieved its primary goal of selecting the efficacious and safe d
May 29, 2026
SEC
Cardiff Oncology disclosed that its licensor, Nerviano Medical Sciences (NMS), has terminated the key license agreement
8-K — Impact 8/10
May 19, 2026
SEC
Cardiff Oncology filed a lawsuit against Nerviano Medical Sciences (NMS) to preemptively challenge NMS's allegation that
8-K — Impact 5/10
Apr 27, 2026
Insider
Aggarwal Ajay sold 400,000 shares
Chief Operating Officer @ $0.00 ($0.00)
Apr 14, 2026
Insider
Smeal Tod sold 300,000 shares
Chief Scientific Officer @ $0.00 ($0.00)
Apr 6, 2026
Insider
Muntner Joshua B sold 486,650 shares
Chief Financial Officer @ $0.00 ($0.00)
Inst.
TWO SIGMA INVESTMENTS, LP — DOUBLED
724,957 shares ($2.0M)
Price Targets
$6.92
+361.1% upside
Strong Buy
Current $1.50
Low $2.00
Median $7.25
High $12.00
6 analysts
$2.00
$12.00
Analyst Ratings
3Strong Buy
9Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 3, 2026 | Craig-Hallum | DOWNGRADE | Buy → Hold |
| Jun 1, 2026 | TD Cowen | DOWNGRADE | Buy → Hold |
| Jun 1, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy → Neutral |
| Feb 25, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
| Jan 28, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.16 ▼ -33.3% | $-0.20 — $-0.11 | 24% YoY | 6 |
| Next Q | $-0.17 ▼ -27.5% | $-0.20 — $-0.13 | 1% YoY | 6 |
| Current FY | $-0.69 ▼ -32.6% | $-0.78 — $-0.56 | 0% YoY | 6 |
| Next FY | $-0.82 ▼ -16.6% | $-0.88 — $-0.69 | -19% YoY | 5 |
Latest Reports
BULLISH
8-K
7/10
Cardiff Oncology released an investor presentation detailing interim Phase 2 CRDF-004 data for onvansertib in first-line
Jun 3, 2026
BULLISH
Press
8/10
Cardiff Oncology announced positive Phase 2 data for onvansertib in first-line RAS-mutated mCRC at ASCO 2026, showing a
Jun 2, 2026
BEARISH
8-K
8/10
Cardiff Oncology disclosed that its licensor, Nerviano Medical Sciences (NMS), has terminated the key license agreement
May 29, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $10.5M | ADD |
| TWO SIGMA INVESTMENTS, LP | $2.0M | DOUBLED |
| MORGAN STANLEY | $662.7K | TRIM |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $530.1K | ADD |
| WELLS FARGO & COMPANY/MN | $235.6K | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 27, 2026 | Aggarwal Ajay | A | $0.00 |
| Apr 14, 2026 | Smeal Tod | A | $0.00 |
| Apr 6, 2026 | Muntner Joshua | A | $0.00 |
| Apr 6, 2026 | Muntner Joshua | A | $0.00 |
| Mar 31, 2026 | Mohindru Mani | A | $0.00 |
Reddit Sentiment
64°
Warm
Bearish
Neutral
Bullish
7 institutional holders with $14.1M total value (5,034,327 shares) as of 2025-Q4. Top holders: VANGUARD, TWO, MORGAN. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 3,722,085 | $10.5M | 73.9% | ADD +36.3% |
| 2 | TWO SIGMA INVESTMENTS, LP | 724,957 | $2.0M | 14.4% | DOUBLED +255.4% |
| 3 | MORGAN STANLEY | 235,834 | $662.7K | 4.7% | TRIM -61.0% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 188,655 | $530.1K | 3.7% | ADD +67.2% |
| 5 | WELLS FARGO & COMPANY/MN | 83,830 | $235.6K | 1.7% | ADD +43.3% |
| 6 | BANK OF AMERICA CORP /DE/ | 41,264 | $116.0K | 0.8% | TRIM -47.2% |
| 7 | FMR LLC | 37,702 | $105.9K | 0.7% | DOUBLED +1144.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 204,010 | 724,957 | +255.4% | $2.0M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 58,519 | 83,830 | +43.3% | $235.6K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 101,800 | 0 | -100.0% | $0.00 | 2025-Q4 |
| MORGAN STANLEY | TRIM | 795,746 | 310,659 | -61.0% | $640.0K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 443,521 | 204,010 | -54.0% | $420.3K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 46,139 | 58,519 | +26.8% | $120.5K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 93,393 | 49,321 | -47.2% | $101.6K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 168,349 | 443,521 | +163.5% | $1.4M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 129,690 | — | $408.5K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 32,283 | 93,393 | +189.3% | $294.2K | 2025-Q2 |
| VANGUARD GROUP INC | ADD | 2,284,917 | 3,115,369 | +36.3% | $9.8M | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 286,853 | 855,540 | +198.3% | $2.7M | 2025-Q1 |
| MORGAN STANLEY | ADD | 542,389 | 698,528 | +28.8% | $2.2M | 2025-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 101,664 | 169,974 | +67.2% | $533.7K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | ADD | 105,227 | 168,349 | +60.0% | $528.6K | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | ADD | 32,064 | 42,244 | +31.7% | $132.6K | 2025-Q1 |
| FMR LLC | DOUBLED | 2,906 | 36,157 | +1144.2% | $113.5K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 483,090 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | ADD | 681,564 | 946,352 | +38.9% | $4.1M | 2024-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 82,946 | 286,853 | +245.8% | $1.2M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 23,213 | 32,064 | +38.1% | $139.2K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 121,293 | — | $323.9K | 2024-Q3 |
4 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 27, 2026 | Aggarwal Ajay | Chief Operating Officer | A | 400,000 | $0.00 | $0.00 |
| Apr 14, 2026 | Smeal Tod | Chief Scientific Officer | A | 300,000 | $0.00 | $0.00 |
| Apr 6, 2026 | Muntner Joshua B | Chief Financial Officer | A | 486,650 | $0.00 | $0.00 |
| Apr 6, 2026 | Muntner Joshua B | Chief Financial Officer | A | 486,650 | $0.00 | $0.00 |
| Mar 31, 2026 | Mohindru Mani | Chief Executive Officer | A | 600,000 | $0.00 | $0.00 |
6 SEC filing reports analyzed. Sentiment: 4 bullish, 2 bearish, 0 mixed, 0 neutral. Avg impact: 7.2/10.
BULLISH
8-K
7/10
Cardiff Oncology released an investor presentation detailing interim Phase 2 CRDF-004 data for onvan
Jun 3, 2026
BEARISH
8-K
8/10
Cardiff Oncology disclosed that its licensor, Nerviano Medical Sciences (NMS), has terminated the ke
May 29, 2026
BEARISH
8-K
5/10
Cardiff Oncology filed a lawsuit against Nerviano Medical Sciences (NMS) to preemptively challenge N
May 19, 2026
BULLISH
8-K
7/10
Cardiff Oncology reported Q1 2026 results with a net loss of $0.18 per share, slightly narrower than
May 14, 2026
BULLISH
8-K
8/10
Cardiff Oncology released positive Phase 2 data for its drug onvansertib in first-line RAS-mutant me
Feb 25, 2026
BULLISH
8-K, 8-K
8/10
Cardiff Oncology reported positive Phase 2 clinical trial results for its lead drug onvansertib in f
Feb 24, 2026
BULLISH
8/10
Cardiff Oncology announced positive Phase 2 data for onvansertib in first-line RAS-mutated mCRC at A
Jun 2, 2026
NEUTRAL
4/10
Cardiff Oncology announced it will present updated Phase 2 data for onvansertib in RAS-mutated mCRC
May 21, 2026
BULLISH
7/10
Cardiff Oncology presented preclinical data at AACR 2026 showing that its PLK1 inhibitor onvansertib
Apr 17, 2026
MIXED
5/10
Cardiff Oncology announced preclinical data showing its PLK1 inhibitor onvansertib enhances the anti
Mar 19, 2026
Current analyst consensus: Strong Buy (86% buy). Based on 14 analysts: 3 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$6.92 mean target
+361.1% upside
Strong Buy (2.13)
$2.00 Low
$12.00 High
| Metric | Value |
|---|---|
| Current Price | $1.50 |
| Target Low | $2.00 |
| Target Mean | $6.92 |
| Target Median | $7.25 |
| Target High | $12.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (2.13) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.16 | $-0.20 | $-0.11 | 23.8% | -33.3% | 0↑ 5↓ | $0.0B | -48.1% | 6 |
| Next Q 2026-09-30 |
$-0.17 | $-0.20 | $-0.13 | 1.0% | -27.5% | 0↑ 5↓ | $0.0B | -44.0% | 6 |
| Current FY 2026-12-31 |
$-0.69 | $-0.78 | $-0.56 | 0.5% | -32.6% | 0↑ 5↓ | $0.0B | -61.3% | 6 |
| Next FY 2027-12-31 |
$-0.82 | $-0.88 | $-0.69 | -18.8% | -16.6% | 0↑ 3↓ | $0.0B | -17.5% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.160 | |
| 7d ago | $-0.160 | |
| 30d ago | $-0.120 | -0.040 |
| 60d ago | $-0.120 | -0.040 |
| 90d ago | $-0.120 | -0.040 |
4 analyst firms have rated this stock: 0 upgrades, 3 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 3, 2026 | Craig-Hallum | DOWNGRADE | Buy | Hold |
| Jun 1, 2026 | TD Cowen | DOWNGRADE | Buy | Hold |
| Jun 1, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Feb 25, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Jan 28, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 9 | 2 | 0 | 0 | 86% | |
| May 1, 2026 | 3 | 9 | 2 | 0 | 0 | 86% | |
| Apr 1, 2026 | 3 | 9 | 2 | 0 | 0 | 86% | |
| Mar 1, 2026 | 3 | 9 | 2 | 0 | 0 | 86% | |
| Feb 1, 2026 | 4 | 9 | 2 | 0 | 0 | 87% | |
| Jan 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
64°
Warm
Bearish
Neutral
Bullish
3 mentions
2 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 19, 2026 | 2 | 58° Warm | 1 | 0 | 2 |
| May 19, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
A few small caps I’m watching into the session
▲ 1
💬 1
⚡ 0.5
Jun 2, 2026
fda
Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting
<p align="center"><em>- The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regime
Jun 2, 2026
short_volume
Short Volume: CRDF — 57.4% short (0.7M / 1.2M)
Short: 707,323 | Exempt: 56,792 | TRF Vol: 1,232,540 | Short Ratio: 57.4% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
other
Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference
<p align="justify">SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company levera
Jun 1, 2026
short_volume
Short Volume: CRDF — 56.1% short (1.9M / 3.4M)
Short: 1,898,463 | Exempt: 267,600 | TRF Vol: 3,381,978 | Short Ratio: 56.1% | Off-exchange volume (dark pool + OTC)
May 27, 2026
short_volume
Short Volume: CRDF — 63.0% short (0.4M / 0.6M)
Short: 388,225 | Exempt: 172 | TRF Vol: 616,180 | Short Ratio: 63.0% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: CRDF — 61.3% short (0.4M / 0.7M)
Short: 442,188 | Exempt: 1,200 | TRF Vol: 720,799 | Short Ratio: 61.3% | Off-exchange volume (dark pool + OTC)
May 21, 2026
fda
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC
Updated Phase 2 CRDF-004 data to be presented during ASCO 2026 rapid oral session on June 2, 2026; investor webcast scheduled for June 3, 2026 at 8:30
May 18, 2026
short_volume
Short Volume: CRDF — 62.1% short (0.4M / 0.6M)
Short: 382,975 | Exempt: 9,775 | TRF Vol: 616,686 | Short Ratio: 62.1% | Off-exchange volume (dark pool + OTC)
May 14, 2026
earnings
Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update
<p align="center"><em>Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phas
Apr 30, 2026
earnings_calendar
CRDF Q1 2026 Earnings After Market Close — 2026-04-30
Apr 28, 2026
other
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
<p>SAN DIEGO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PL
Apr 21, 2026
routine
Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026
<p>SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhib
Apr 17, 2026
fda
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting
Onvansertib in combination with trastuzumab deruxtecan demonstrated enhanced antitumor activity, including tumor regression and apoptosis in HER2-low
Apr 15, 2026
short_volume
Short Volume: CRDF — 55.1% short (0.3M / 0.5M)
Short: 291,264 | Exempt: 1 | TRF Vol: 528,326 | Short Ratio: 55.1% | Off-exchange volume (dark pool + OTC)
Apr 9, 2026
leadership
Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth
<p align="center"><em>Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive Officer</em><br><br><em>Appoints industry v